Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.
Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.
Metformin combination products
Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone
- Conditions
- Interventions
- First Posted Date
- 2008-10-01
- Last Posted Date
- 2016-11-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 484
- Registration Number
- NCT00763815
- Locations
- 🇺🇸
Sanofi-Aventis Investigational Site Number 840708, Kalamazoo, Michigan, United States
🇺🇸Sanofi-Aventis Investigational Site Number 840792, Columbia, South Carolina, United States
🇺🇸Sanofi-Aventis Investigational Site Number 840855, Mobile, Alabama, United States
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
- Conditions
- Interventions
- First Posted Date
- 2008-10-01
- Last Posted Date
- 2016-12-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 484
- Registration Number
- NCT00763451
- Locations
- 🇺🇦
Sanofi-Aventis Administrative Office, Kiev, Ukraine
Safety and Efficacy of TAK-559 in Combination With Metformin in Patients With Type 2 Diabetes Mellitus.
- First Posted Date
- 2008-09-30
- Last Posted Date
- 2012-02-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 15
- Registration Number
- NCT00762957
A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.
- Conditions
- Interventions
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2016-07-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1072
- Registration Number
- NCT00755287
A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.
- Conditions
- Interventions
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 666
- Registration Number
- NCT00754988
Efficacy of Pioglitazone and Fortamet Combination Therapy in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2010-07-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 312
- Registration Number
- NCT00754403
Study of Rimonabant/Metformin Combinations to Investigate Diabetes (Blood Sugar) Control in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2016-05-17
- Lead Sponsor
- Sanofi
- Registration Number
- NCT00754689
- Locations
- 🇺🇸
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States
Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients
- Conditions
- Interventions
- First Posted Date
- 2008-09-11
- Last Posted Date
- 2012-09-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 515
- Registration Number
- NCT00751114
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
Switch From Metformin Monotherapy to a Bitherapy With Metformin and Repaglinide
- First Posted Date
- 2008-09-03
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 906
- Registration Number
- NCT00745433
A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.
- Conditions
- Interventions
- First Posted Date
- 2008-09-01
- Last Posted Date
- 2016-08-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 326
- Registration Number
- NCT00744367
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.